Enzychem Lifesciences Corporation (KOSDAQ:183490)
South Korea
· Delayed Price · Currency is KRW 990.00
-27.00 (-2.65%)
Mar 25, 2026, 7:48 AM KST
Enzychem Lifesciences Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 67,751 | 77,378 | 76,039 | 26,638 | 22,975 | Upgrade
|
| Other Revenue | - | -0 | - | -0 | - | Upgrade
|
| Revenue | 67,751 | 77,378 | 76,039 | 26,638 | 22,975 | Upgrade
|
| Revenue Growth (YoY) | -12.44% | 1.76% | 185.46% | 15.94% | -11.01% | Upgrade
|
| Cost of Revenue | 64,368 | 73,068 | 71,691 | 24,221 | 22,689 | Upgrade
|
| Gross Profit | 3,383 | 4,310 | 4,348 | 2,416 | 286.72 | Upgrade
|
| Selling, General & Admin | 12,931 | 12,215 | 12,017 | 9,834 | 10,859 | Upgrade
|
| Research & Development | 3,546 | 4,421 | 5,434 | 6,558 | 9,501 | Upgrade
|
| Amortization of Goodwill & Intangibles | 405.96 | 411.31 | 533.08 | 271.55 | 231.12 | Upgrade
|
| Operating Expenses | 21,654 | 20,686 | 19,081 | 17,078 | 21,040 | Upgrade
|
| Operating Income | -18,270 | -16,376 | -14,733 | -14,662 | -20,754 | Upgrade
|
| Interest Expense | -201.47 | -238.7 | -620.09 | -10,030 | -9,508 | Upgrade
|
| Interest & Investment Income | 3,817 | 5,207 | 5,489 | 3,976 | 963.71 | Upgrade
|
| Earnings From Equity Investments | -770.19 | -2,176 | 26.87 | -13.64 | -445.14 | Upgrade
|
| Currency Exchange Gain (Loss) | -102.28 | 244.33 | -34.38 | -164.71 | -60.59 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,203 | -6,660 | 41.19 | -7.09 | 292.36 | Upgrade
|
| EBT Excluding Unusual Items | -14,324 | -20,000 | -9,830 | -20,901 | -29,512 | Upgrade
|
| Gain (Loss) on Sale of Investments | -16.98 | -1,938 | 3.65 | 3.57 | 4.39 | Upgrade
|
| Gain (Loss) on Sale of Assets | -156.11 | -0.45 | -19.5 | 8.12 | -13.27 | Upgrade
|
| Asset Writedown | -3,743 | -145.56 | -32.74 | -4,692 | 16.05 | Upgrade
|
| Pretax Income | -18,240 | -22,084 | -9,879 | -25,581 | -29,504 | Upgrade
|
| Income Tax Expense | -147.22 | 3.12 | -476.3 | -488.27 | -1,640 | Upgrade
|
| Earnings From Continuing Operations | -18,092 | -22,088 | -9,403 | -25,093 | -27,865 | Upgrade
|
| Minority Interest in Earnings | -39.15 | -19.01 | 76.24 | - | - | Upgrade
|
| Net Income | -18,132 | -22,107 | -9,326 | -25,093 | -27,865 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | -159.59 | -941.77 | Upgrade
|
| Net Income to Common | -18,132 | -22,107 | -9,326 | -24,934 | -26,923 | Upgrade
|
| Shares Outstanding (Basic) | 77 | 82 | 85 | 79 | 50 | Upgrade
|
| Shares Outstanding (Diluted) | 77 | 82 | 85 | 79 | 50 | Upgrade
|
| Shares Change (YoY) | -5.36% | -3.60% | 7.75% | 56.10% | 3.93% | Upgrade
|
| EPS (Basic) | -234.00 | -270.00 | -109.81 | -316.34 | -533.20 | Upgrade
|
| EPS (Diluted) | -234.00 | -270.00 | -110.00 | -316.34 | -533.20 | Upgrade
|
| Free Cash Flow | -11,775 | -897.74 | -12,506 | -22,277 | -24,407 | Upgrade
|
| Free Cash Flow Per Share | -151.96 | -10.96 | -147.25 | -282.63 | -483.37 | Upgrade
|
| Gross Margin | 4.99% | 5.57% | 5.72% | 9.07% | 1.25% | Upgrade
|
| Operating Margin | -26.97% | -21.16% | -19.38% | -55.04% | -90.33% | Upgrade
|
| Profit Margin | -26.76% | -28.57% | -12.26% | -93.60% | -117.18% | Upgrade
|
| Free Cash Flow Margin | -17.38% | -1.16% | -16.45% | -83.63% | -106.23% | Upgrade
|
| EBITDA | -15,134 | -12,918 | -11,221 | -12,273 | -18,643 | Upgrade
|
| EBITDA Margin | -22.34% | -16.69% | -14.76% | -46.07% | -81.14% | Upgrade
|
| D&A For EBITDA | 3,136 | 3,458 | 3,512 | 2,389 | 2,111 | Upgrade
|
| EBIT | -18,270 | -16,376 | -14,733 | -14,662 | -20,754 | Upgrade
|
| EBIT Margin | -26.97% | -21.16% | -19.38% | -55.04% | -90.33% | Upgrade
|
| Advertising Expenses | 323.9 | 520.5 | 299.56 | 456.54 | 443.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.